Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

SYNTA PHARMACEUTICALS CORP.

SummaryNewsRatingsCalendarCompany 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Synta Pharmaceuticals Corp. : Synta to Present at the Stifel 2013 Healthcare Conference

09/04/2013 | 08:00am EST

Synta Pharmaceuticals Corp. (NASDAQ: SNTA) announced today that the Company will present at the Stifel 2013 Healthcare Conference on Wednesday, September 11, at 3:15 p.m. (EDT) in Boston.

A live audio webcast and replay of the presentation will be available on the "Investors" section of the Company's website, www.syntapharma.com.

About Synta Pharmaceuticals

Synta Pharmaceuticals Corp. is a biopharmaceutical company focused on discovering, developing, and commercializing small molecule drugs to extend and enhance the lives of patients with severe medical conditions, including cancer and chronic inflammatory diseases. Synta has a unique chemical compound library, an integrated discovery engine, and a diverse pipeline of clinical- and preclinical-stage drug candidates with distinct mechanisms of action and novel chemical structures. All Synta drug candidates were invented by Synta scientists using our compound library and discovery capabilities. For more information, please visit www.syntapharma.com.

Investor Relations:
Synta Pharmaceuticals Corp.
George Farmer, 781-541-7213
gfarmer@syntapharma.com
or
Argot Partners
Andrea Rabney, 212-600-1494
andrea@argotpartners.com


© Business Wire 2013
All news about SYNTA PHARMACEUTICALS CORP.
01/11B. Riley Lowers Madrigal Pharmaceuticals' PT to $131 from $174 to Account for Lower Mar..
MT
01/10Dominic F. Labriola Joins Madrigal Pharmaceuticals as Chief Data and Analytics Officer
AQ
01/10Madrigal Pharmaceuticals, Inc Appoints Dominic F. Labriola as Chief Data and Analytics ..
CI
2021Madrigal Provides Update on Timeline for Topline Results from the Phase 3 MAESTRO-NAFLD..
AQ
2021Madrigal Pharmaceuticals Delays Topline Results From Phase 3 Liver Trial Due to Staffin..
MT
2021Madrigal Provides Update on Timeline for Topline Results from the Phase 3 MAESTRO-NAFLD..
AQ
2021Madrigal Pharmaceuticals, Inc. Provides Update on Timeline for Topline Results from the..
CI
2021Madrigal Pharmaceuticals Announces Participation at Two Upcoming Virtual Investor Confe..
AQ
2021Positive Resmetirom Data from Completed Open-Label Portion of Phase 3 MAESTRO-NAFLD-1 C..
AQ
2021Madrigal Pharmaceuticals Posts Wider Q3 Loss Amid Increased Spending
MT
More news
Analyst Recommendations on SYNTA PHARMACEUTICALS CORP.
More recommendations
Managers and Directors
Paul A. Friedman Chairman, President & Chief Executive Officer
Alex G. Howarth Chief Financial Officer
Rebecca A. Taub Director & Chief Medical Officer
Keith R. Gollust Independent Director
David V. Milligan Independent Director
Sector and Competitors
1st jan.Capi. (M$)
SYNTA PHARMACEUTICALS CORP.1 341
GILEAD SCIENCES, INC.-1.16%90 027
REGENERON PHARMACEUTICALS-2.58%64 327
VERTEX PHARMACEUTICALS6.58%59 510
WUXI APPTEC CO., LTD.-3.73%52 722
BIONTECH SE-23.97%47 338